Why is "Celgene" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-05-03 08:20:40
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Celgene entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-05-03 and was most recently seen on 2026-05-03.
Wikipedia Overview
Celgene Corporation is an American pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS) since its acquisition in 2019.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
u s shares highlights celgene corporation 843792015 - FOREX.com
-
BMS calls time on Zymeworks collab, ending work on bispecific - Fierce Biotech
-
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules - Reuters
-
Claim your share of the $239M Celgene securities class action settlement - Claim Depot
-
Total revenue of Celgene from 2016 to 2018, by therapeutic area - Statista
-
Celgene Inks $239M Investor Deal Over Drug Pipeline Claims - Law360
-
Bristol Myers Reaches $239M Settlement Over Psoriasis, MS Drugs - Claims Journal
-
Bristol-Myers to Face $6.7 Billion Celgene Deal Payout Suit (1) - Bloomberg Law News
-
New York judge revives Bristol Myers dispute over Celgene deal - Endpoints News
-
Cabaletta picks up the pace with new commercial chief from Legend, Celgene - Fierce Pharma
-
List of 12 Acquisitions by Celgene (Apr 2026) - Tracxn
-
Bristol-Myers Reaches $239 Million Celgene Investor Deal (2) - Bloomberg Law News
-
Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies - CNBC
-
Bristol-Myers Must Face Trimmed $6.7B Celgene Investor Suit - Law360
-
The Price of Remission: This Cancer Drug Saves Lives — but Costs a Fortune. I Wanted to Know Why. - ProPublica
-
Celgene top products revenues 2013-2018 - Statista
-
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing - statnews.com
-
A glimpse inside Bristol Myers Squibb’s integration with Celgene - Pharma Voice
-
Bristol-Myers scores first big deal of 2019 with $74B buyout of oncology bigwig Celgene - Fierce Pharma
-
Bristol-Myers to buy Celgene in a $74 billion deal; Celgene shares surge - CNBC
-
For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects - statnews.com
-
Celgene, with strong Phoenix presence, acquired by Bristol-Myers Squibb - Flinn Foundation |
-
Bristol-Myers scores critical endorsements for its embattled Celgene merger - statnews.com
-
Is It Too Late to Buy Celgene Stock? - Yahoo Finance
-
Celgene v. Sun Pharma Global: Satisfying Subject Matter Jurisdiction Under § 271(e)(2) - Mintz
-
Celgene Odds Are in Investors’ Favor - WSJ
-
Celgene pens pact to join Bristol-Myers, Pfizer in R&D race - Fierce Biotech
-
Enhanced Genomics appoints Katerina Leftheris to Board of Directors - PMLiVE
-
Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 - Fierce Biotech
-
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban - Fierce Pharma
-
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing - PR Newswire
-
AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers - AstraZeneca
-
Celgene pledges to limit price hikes—or does it? - Fierce Pharma
-
Bristol-Myers Stock Is Falling Because the Celgene Merger May Not Make Sense - Barron's
-
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace
-
Deal of the Year: Bristol-Myers Squibb buys Celgene - BioPharma Dive
-
Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal - Reuters
-
It had to happen: Ex-Celgene shareholders sue Bristol Myers Squibb for $6.4B in lost CVR cash, claiming 'blatant misconduct' - Fierce Pharma
-
Bristol-Myers to buy Celgene in industry-shaking $74B deal - BioPharma Dive
-
Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal - statnews.com
-
BMS completes $74bn Celgene acquisition - PharmaTimes
-
Bristol-Myers’ Binary Bet on Celgene Drugs Makes a Splash in Debut - Barron's
-
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS - Fierce Pharma
-
Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk's STAR* Technology Platform - PR Newswire
-
Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion (Published 2019) - The New York Times
-
Celgene Can’t Cure the Biotech Blues - WSJ
-
Bristol-Myers Squibb $74-Billion Buy of Celgene: Products, Pipelines, and Manufacturing - DCAT Value Chain Insights
-
Celgene, CRT strike mRNA translation cancer R&D pact - Fierce Biotech
-
Bristol axes two early Celgene projects | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
The $74-Billion Marriage of Bristol-Myers Squibb and Celgene - DCAT Value Chain Insights
-
Celgene cans phase 3 trial of $710M Crohn’s drug GED-0301 - Fierce Biotech
-
Bristol-Myers Squibb acquires Celgene, marrying Opdivo maker with Revlimid maker - USA Today
-
Celgene buys Juno for $9B, deepening bet on CAR-T - BioPharma Dive
-
Bristol Myers nabs long-sought FDA nod for Celgene's MS drug ozanimod, but pandemic delays launch - Fierce Pharma
-
Celgene wins approval for drug key to Bristol buyout - BioPharma Dive
-
Celgene, say goodbye to Otezla: BMS agrees to sell psoriasis drug to clear $74B merger - Fierce Pharma
-
Bluebird, Celgene to share U.S. costs, profits on lead cancer CAR-T - Fierce Biotech
-
Bristol-Myers Squibb to Acquire Celgene for About $74 Billion - WSJ
-
BMS can breathe easier now: Celgene’s Revlimid has escaped a big patent challenge - Fierce Pharma
-
Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan - Fierce Pharma
-
Celgene splashes out $300M on Delinia autoimmune biotech buy - Fierce Biotech
-
Bristol-Myers’ gamble on Celgene pipeline prospects - BioPharma Dive
-
Celgene Shares Slide as Key Bristol-Myers Investor Queries $74 Billion Takeover - thestreet.com
-
Celgene and AstraZeneca provide update on the FUSION clinical trial programme - AstraZeneca
-
Celgene hands PD-1 tislelizumab med back to BeiGene, forfeiting $150M - Fierce Biotech
-
Anokion autoimmune pact rides out BMS-Celgene merger - Fierce Biotech
-
Celgene and Natco in generic lenalidomide battle - Generics and Biosimilars Initiative
-
Bristol-Myers to Buy Celgene in $74 Billion Cancer-Drug Bet - Bloomberg.com
-
Celgene bags Beigene PD-1 drug for $263M up front - Fierce Biotech
-
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire
-
Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer - PR Newswire
-
Drug maker Bristol-Myers Squibb to buy Celgene in $74bn deal - Phys.org
-
J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact Biomedicines - Fierce Biotech
-
Bristol-Myers Squibb to buy Celgene in $74-billion bet on cancer treatments - Los Angeles Times
-
Chutes & Ladders—Former Celgene CEO Alles takes the top job at TORL - Fierce Biotech
-
Activist investor Starboard Value says it will oppose Bristol-Myers' $74 billion deal for Celgene - CNBC
-
Is Celgene's Beat-And-Raise Enough To Outweigh MS Drug Woes? - Investor's Business Daily
-
Bristol-Myers Squibb buying Celgene in $74B deal - Fox Business
-
As Celgene becomes BMS, its I&I lead lands CEO job at Takeda spinoff - Fierce Biotech
-
FDA delays decision on Bristol Myers cell therapy, putting Celgene deal payouts in jeopardy - BioPharma Dive
-
Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets - PR Newswire
-
Bristol-Myers unveils team to lead R&D after Celgene deal closes - Fierce Biotech
-
Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlements - Fierce Pharma
-
Celgene to sell psoriasis drug Otezla to Amgen for $13 billion to clear antitrust hurdle - Los Angeles Times
-
Celgene repeatedly raised Revlimid's price to hit aggressive sales targets, congressional probe finds - Fierce Pharma
-
Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada - Fierce Biotech
-
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition - CNBC
-
Celgene, BMS Sued Over Merger’s Effects on Drug Development Contract - Law Street Media
-
Celgene to buy Juno for $9 billion to boost cancer pipeline - Reuters
-
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb - The Motley Fool
-
Celgene aims to quell growth worries with $7B Impact deal - BioPharma Dive
-
Nantcell announces new Celgene Investment - ImmunityBio
-
BMS Completes $74 Billion Celgene Takeover - BioSpace
-
Acceleron takes back drug rights from Celgene to start pulmonary push - Fierce Biotech
-
Bristol Myers will likely settle the $6.4B Celgene CVR lawsuit at a discount, analyst says. Here's why - Fierce Pharma
-
BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing - Fierce Pharma
-
With Bristol Myers' latest CAR-T filing, Celgene investors inch closer to payout - Fierce Biotech
-
2 months after BMS megamerger, Celgene's JAK inhibitor to get priority review - Fierce Biotech
-
Successful Integration With Celgene During the Pandemic - Bristol Myers Squibb
-
Celgene taps Bristol-Myers sales force to bolster key blood cancer launches - Fierce Pharma
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.